Study wrapper · #905
Semaglutide vs. liraglutide and incidence of diabetes and cardiovascular disease: A target trial emulation using real-world data.
Cannon EJ, Wang W, Norby FL, et al. British journal of clinical pharmacology. 2026.
DOI: 10.1002/bcp.70711PubMed: 42464447
Editor's note
This target-trial emulation matched over 57,000 GLP-1 users and is directly relevant to semaglutide's metabolic profile. The lower diabetes incidence versus liraglutide is a meaningful signal, though the effect emerged only after the first six months and the cardiovascular comparison was underpowered. Observational design means residual confounding cannot be ruled out.
Plain-language abstract
In a large real-world comparison, people prescribed semaglutide for weight management had a lower risk of developing diabetes over one year than those prescribed liraglutide. No difference in cardiovascular events was detected.
Related coverage
Mixed
Hunger pain and its reduction; qualitative insight from people with schizophrenia on semaglutide.
International journal of qualitative studies on health and well-beingn=——2026
Weak / none
Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting.
Journal of enzyme inhibition and medicinal chemistryn=——2026
Mixed
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
Journal of obstetrics and gynaecologyn=——2026